Myomo Appoints Micah Mitchell as Chief Commercial Officer
July 09 2018 - 8:00AM
Business Wire
Company Establishes New Executive Position to
Oversee Scaling Up of Commercial Operations
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a
wearable medical robotics company, announced today that Micah
Mitchell is joining the company as chief commercial officer (CCO),
a newly created executive role. The addition of a CCO reflects
Myomo’s transition from a controlled introduction of its
proprietary MyoPro product line to expansion of its sales,
marketing, and distribution activities to address the large unmet
need of expanded mobility for individuals with arm and hand
paralysis.
Mitchell will report to CEO Paul R. Gudonis and work with Davie
Mendelsohn, Myomo’s vice president of sales and clinical services,
to grow the company’s network of MyoPro Centers of Excellence,
expand its field staff of business development and clinical
professionals, and generate demand for its product line among
patients, physicians and therapists.
Mitchell has extensive experience growing revenues for companies
in the durable medical equipment industry, including companies that
provide customized wheelchair and mobility solutions to those with
paralysis due to spinal cord injuries and other neurological
conditions. He has served in sales management and executive roles
at Invacare, Alliance Seating and Mobility, and Apria Healthcare
Group, where he expanded their field sales organizations, conducted
direct-to-consumer marketing campaigns, and obtained reimbursement
for their products to increase patient access to the
technology.
“Now that we have embarked on scaling up our commercial
operations to bring the MyoPro to the many people who could benefit
from this life-changing product line, we are pleased to have an
executive of Micah’s stature join our senior management team,”
Gudonis said. “He has a track record of growing revenues, and he
will collaborate with our chief marketing officer, chief medical
officer and operations management to develop and implement programs
that provide the MyoPro to a greater number of patients through our
clinical channel partners.”
Mitchell earned a BS in Economics from Baylor University and an
MBA from the McCombs School of Business at The University of Texas
at Austin.
About Myomo
Myomo, Inc. is a wearable medical robotics company that offers
expanded mobility for those suffering from neurological disorders
and upper limb paralysis. Myomo develops and markets the MyoPro
product line. MyoPro is a powered upper limb orthosis designed to
restore function to the weakened or paralyzed arms of patients
suffering from CVA stroke, brachial plexus injury, traumatic brain
or spinal cord injury, ALS or other neuromuscular disease or
injury. It is currently the only marketed device that, sensing a
patient’s own EMG signals through non-invasive sensors on the arm,
can restore an individual’s ability to perform activities of daily
living, including feeding themselves, carrying objects and doing
household tasks. Many are able to return to work, live
independently and reduce their cost of care. Myomo is headquartered
in Cambridge, Massachusetts, with sales and clinical professionals
across the U.S. For more information, please visit
www.myomo.com.
Forward Looking Statements
This press release contains forward-looking statements regarding
the Company's future business expectations, including the hiring of
a Chief Commercial Officer and its impact on the business, the
Company’s expansion of sales, marketing and distribution
activities, and scale-up of commercial operations, which are
subject to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. These forward-looking statements are
only predictions and may differ materially from actual results due
to a variety of factors. Our actual results could differ materially
from those anticipated in these forward looking statements for many
reasons, including, without limitation, risks related to regulatory
approval and market acceptance of our products, and the other risk
factors contained in our filings made with the Securities and
Exchange Commission. More information about factors that
potentially could affect Myomo's financial results is included in
Myomo's filings with the Securities and Exchange Commission. The
Company cautions readers not to place undue reliance on any such
forward-looking statements, which speak only as of the date made.
The Company disclaims any obligation subsequently to revise any
forward-looking statements to reflect events or circumstances after
the date of such statements or to reflect the occurrence of
anticipated or unanticipated events.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180709005242/en/
For Myomo:ir@myomo.comorInvestor Relations:PCG
AdvisoryVivian Cervantes,
646-863-6274vivian@pcgadvisory.comorPublic
Relations:GreenoughRachel Robbins,
617-275-6521rrobbins@greenough.biz
Myomo (AMEX:MYO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Myomo (AMEX:MYO)
Historical Stock Chart
From Sep 2023 to Sep 2024